Prediabetic State Clinical Trial
— PROVEN-DIAOfficial title:
Effectiveness of the Diabetes Prevention Program on the Incidence of Type 2 Diabetes Mellitus Among Brazilian Individuals: Randomized Clinical Trial (PROVEN-DIA Study)
Verified date | April 2024 |
Source | Beneficência Portuguesa de São Paulo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this multicenter controlled randomized trial is to assess the effectiveness of Brazilian Diabetes Prevention Program (face-to-face or e-health) in incidence of T2D with, at least, 1590 adults at high risk of developing T2D during 3-yr follow-up. Our primary outcomes are the incidence of T2D, MVPA (min/week), prevalence of physical inactivity, quality of life, BALANCE DI, CDHI, body weight (kg), and biomarkers of glycemia. In addition, social, cultural, educational and geographical factors at community levels will also be analyzed throughout the follow-up to verify their association with the incidence of T2D.
Status | Not yet recruiting |
Enrollment | 1590 |
Est. completion date | December 31, 2029 |
Est. primary completion date | December 31, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria - Be 18 years or older (no maximum age for being eligible) - Have a body mass index (BMI) between 25 and 34,9kg/m² - Have, at least, one electronic device (includes any of the following devices): - Computer - Laptop/notebook - Tablet - Smartphone - Have access to internet (broadband, 3G, 4G, 5G, among others) - Without previous nutritional counseling (within 6 months prior to the recruitment/randomization/intervention) - Living near the research center (at maximum 60 minutes of walking) - Had a blood test result in the prediabetes range within the last three months prior to the recruitment/randomization/intervention (includes any of these tests and results): - Hemoglobin levels (HbA1c): 5.7-6.4% - Fasting blood glucose: 100-125 mg/dL - Blood glucose 2 hours after an oral glucose tolerance: 140-199 mg/dL Exclusion Criteria - Diagnosis of Diabetes Mellitus - In secondary prevention for Cardiovascular Disease (myocardial infarction, unstable angina or stroke in the past six months) - Exclusion for underlying disease or condition likely to limit life span and/or increase risk of interventions o Cardiovascular disease - Congestive Heart Failure (New York Heart Association Functional Class > 2) - Uncontrolled hypertension - Lung disease (asthma or Chronic Obstructive Pulmonary Disease) - Gastrointestinal disease - Renal disease - Major psychiatric disorder - Anemia (hematocrit < 36.0% in men or < 33.0% in women) - Weight loss of > 10% in past 6 months for any reason, except post-partum weight loss - Excessive alcohol intake - Medication use (antihypertensives, antibiotics, corticoids, antipsychotic, antineoplastic agents, phenytoin, amphetamines, and prescript weight-loss drugs) - Likely to move away from participating clinics in next 5 years - Another household member is a participant or staff member in the study - Unable or unwilling to give informed consent (subject refused to sign the Free and Informed Consent Form) - Current participation in another Randomized Clinical Trial whose main purpose interferes with any of the interventions and primary outcomes of this study (for instance, food consumption and physical activity level) - Participant of the pilot Randomized Clinical Trial ( Brazilian Diabetes Prevention Program: Pilot Study (PROVEN-Dia), NCT05689658) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Beneficência Portuguesa de São Paulo |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of type 2 diabetes mellitus | to analyze the incidence of type 2 diabetes mellitus | 36 months | |
Secondary | Mean value of Glycated Hemoglobin level (HbA1c in %) | to compare mean HbA1c(%) obtained through laboratory exams/tests between groups | 6, 12, 24 and 36 months | |
Secondary | Mean value of Fasting Blood Glucose (mg/dL) | to compare mean fasting blood glucose (mg/dL) obtained through laboratory exams/tests between groups | 6, 12, 24 and 36 months | |
Secondary | Number of Participants with controlled Fasting blood glucose (<126mg/dL) | to compare the proportion of individuals with controlled blood glucose (<126mg/dl) obtained through laboratory exams/tests without the use of hypoglycemic medication | 6, 12, 24 and 36 months | |
Secondary | Number of Participants with controlled Glycated Hemoglobin level (<6.4%) | to compare the proportion of individuals with HbA1c (<6.4%) obtained through laboratory exams/tests without the use of hypoglycemic medication | 6, 12, 24 and 36 months | |
Secondary | body weight | to compare mean weight (kg) between groups | 6, 12, 24 and 36 months | |
Secondary | Number of Participants who performed, at least, 150 minutes of moderate-to-vigorous physical activity obtained thourgh International Physical Activity Questionnaire short form | to compare the proportion of individuals who are physically active (>150 minutes of moderate to vigorous physical activity) and inactive (<150 minutes of moderate to vigorous physical activity) between groups | 6, 12, 24 and 36 months | |
Secondary | Minutes spent on moderate-to-vigorous physical activity | to compare mean time in minutes of practice of moderate/vigorous physical activity over a week between groups | 6, 12, 24 and 36 months | |
Secondary | Moderate-to-vigorous physical activity and sedentary behavior | to compare the proportion of individuals engaging in moderate or vigorous physical activity and sedentary behavior | 6, 12, 24 and 36 months | |
Secondary | Physical activity | to compare the proportion of individuals who engage in 150 minutes or more of physical activity per week | 6, 12, 24 and 36 months | |
Secondary | Sedentary behavior | to compare the proportion of sedentary individuals | 6, 12, 24 and 36 months | |
Secondary | Quality of diet (Mean score of the Brazilian Cardioprotective Nutritional Program dietary index) | to compare mean score of Brazilian Cardioprotective Nutritional Program dietary index (BALANCE DI) between groups Minimum: 0 Maximum: 40 When higher the score, better the quality of diet | 6, 12, 24 and 36 months | |
Secondary | Mean of kcal from ultra processed food intake | to compare the mean caloric intake (kcal) from ultra-processed foods obtained through two 24-hour Dietary Recall applied within a period of fifiteen days | 6, 12, 24 and 36 months | |
Secondary | Delta value (Change score from baseline to 6, 12, 24 and 36 months) for each domain of Quality of life obtained through Short Form Health Survey (SF-36) | to analyze the quality of life based on delta value of the eight domains (Functional capacity, Physical aspects, Pain, General health status, Vitality, Social aspects, Emotional aspects and Mental health) When higher the score, better the quality of life related to the assessed domain | 6, 12, 24 and 36 months | |
Secondary | Cost | To compare the cost of interventions. To estimate healthcare system costs, we will consider only direct medical costs, which include screening costs, intervention costs, and costs of healthcare service utilization. To estimate social costs, we will consider not only direct medical costs but also non-medical direct costs, such as transportation, food, and accommodation expenses reported by participants when seeking medical assistance, as well as time spent traveling to and participating in group sessions. Additionally, we will include indirect costs, calculated based on the assumption that each necessary hospitalization results in a loss of 9 hours of paid work and each outpatient visit results in a loss of half a day (4.5 hours) of paid work | 36 months | |
Secondary | Scholarity | To analyze the correlation between years of study and the incidence of type 2 diabetes | 36 months | |
Secondary | Geo-Stratified Analysis | T2DM incidence across Brazillian five geographic regions (South, Southeast, Midwest, West, and Northwest) | 36 months | |
Secondary | Household income | Association between T2DM incidence and individual Low or high income (accessed by ABEP - Critério Brasil 2022 questionnaire) | 36 months | |
Secondary | Neighbourhood value | correlation between neighborhood value (as assessed using the Gini index) and incidence of type 2 diabetes (DM2) | 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05424107 -
A Mediterranean Intervention on Prediabetic Children
|
N/A | |
Recruiting |
NCT02681887 -
Effect of Melatonin on Cardiometabolic Risk- FULL
|
Phase 3 | |
Completed |
NCT04088461 -
Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine
|
Phase 4 | |
Recruiting |
NCT02561377 -
Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics)
|
N/A | |
Completed |
NCT02551640 -
Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients
|
N/A | |
Completed |
NCT02678390 -
Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes
|
N/A | |
Completed |
NCT02459691 -
Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)
|
N/A | |
Completed |
NCT01479933 -
Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes
|
N/A | |
Completed |
NCT01671293 -
Multicomponent Telecare Model for Supporting Prediabetes Patients
|
N/A | |
Completed |
NCT00960973 -
The Effect of Vitamin K Supplementation on Glucose Metabolism
|
Phase 4 | |
Completed |
NCT00455325 -
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
|
Phase 2 | |
Recruiting |
NCT05123963 -
Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors
|
N/A | |
Recruiting |
NCT05340868 -
Genetics of the Acute Response to Oral Semaglutide
|
N/A | |
Recruiting |
NCT04984421 -
IMplementation of the Family Support PRogramme A Healthy School Start to Prevent OVErweight and Obesity (IMPROVE)
|
N/A | |
Recruiting |
NCT04131582 -
Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes
|
Phase 3 | |
Recruiting |
NCT04134650 -
Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes
|
Phase 3 | |
Recruiting |
NCT05347030 -
Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population
|
N/A | |
Completed |
NCT04074148 -
Effectiveness of Diabetes Prevention Education Program on Diabetes Prevention Among Prediabetes Population in Nepal
|
N/A | |
Recruiting |
NCT05050266 -
Enhancing Mental and Physical Health of Women Veterans
|
N/A | |
Completed |
NCT02684565 -
Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects
|
N/A |